Ravulizumab – July 2023

• Brand names:
  • Ultomiris®
• Pharmaceutical Company:
  • Alexion Pharmaceuticals Australasia Pty Ltd
• Condition/Indication: Atypical haemolytic uraemic syndrome (aHUS)
• Meeting Date: July 2023
• Public Summary Document (PSD) March 2023 July 2023 PBAC Meeting - (PDF 887KB)
• Public Summary Document (PSD) March 2023 July 2023 PBAC Meeting - (Word 224KB)

Related public summary documents

• Ravulizumab – March 2023